AR025343A1 - Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante - Google Patents

Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante

Info

Publication number
AR025343A1
AR025343A1 ARP000104319A ARP000104319A AR025343A1 AR 025343 A1 AR025343 A1 AR 025343A1 AR P000104319 A ARP000104319 A AR P000104319A AR P000104319 A ARP000104319 A AR P000104319A AR 025343 A1 AR025343 A1 AR 025343A1
Authority
AR
Argentina
Prior art keywords
vitamin
oprevenate
treat
drug
states
Prior art date
Application number
ARP000104319A
Other languages
English (en)
Original Assignee
Ferrosan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrosan As filed Critical Ferrosan As
Publication of AR025343A1 publication Critical patent/AR025343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se ha hallado un sistema de suministro farmacéutico que comprende una formulacion de liberacion lenta de vitamina C (ácido ascorbico) y una formulacion deliberacion simple de vitamina E (tocoferol) para elevar y mantener la concentracion de estasvit aminas en el plasma sanguíneo en una proporcion deaproximadamente 2,2:1. Se ha hallado que la concentracion y proporcion de estos oxidantes en un estado estacionario son críticos en la prevencion y tratamientode desordenes relacionados con elestrés oxidante tales como arteriosclerosis y diabetes y desordenes degenerativos nerviosos tales como la Enfermedad deAlzheimer.
ARP000104319A 1999-08-20 2000-08-22 Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante AR025343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199901145 1999-08-20

Publications (1)

Publication Number Publication Date
AR025343A1 true AR025343A1 (es) 2002-11-20

Family

ID=8101522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104319A AR025343A1 (es) 1999-08-20 2000-08-22 Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante

Country Status (8)

Country Link
EP (1) EP1210079A2 (es)
JP (1) JP2003507419A (es)
AR (1) AR025343A1 (es)
AU (1) AU6558900A (es)
NZ (1) NZ517833A (es)
PL (1) PL356667A1 (es)
RU (1) RU2309733C2 (es)
WO (1) WO2001013901A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078296A2 (en) * 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
MXPA04009412A (es) * 2002-03-28 2005-12-12 Oxis Int Inc Metodos neuroprotectores, composiciones y metodos para seleccion de los mismos.
MXPA05007278A (es) * 2003-01-17 2005-09-30 Vital Health Sciences Pty Ltd Compuestos que tienen propiedades anti-proliferativas.
KR20060069850A (ko) * 2003-09-05 2006-06-22 마티아스 라트 비타민 ｃ, 마그네슘, 녹차 추출물을 포함하는 심장혈관계질환을 억제하기 위한 약제 조성물
ES2557475T3 (es) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
CA3045702A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Phosphorylation process of complex alcohols
JPWO2022059776A1 (es) * 2020-09-17 2022-03-24

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0176772B1 (de) * 1984-08-30 1989-03-29 RODISMA Pharmazeutische Produkte GmbH Verfahren zur Retardierung von Vitamin C und E
JPH07227256A (ja) * 1993-12-24 1995-08-29 Takeda Chem Ind Ltd 経口液剤
IL109539A0 (en) * 1994-05-03 1994-08-26 Yissum Res Dev Co Substained-release pharmaceutical system for the delivery of antioxidants
US5560928A (en) * 1995-06-23 1996-10-01 Defelice; Stephen L. Nutritional and/or dietary composition and method of using the same
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IT1283478B1 (it) * 1996-07-22 1998-04-21 Roberto Valducci Composizioni per integrazione nutrizionale comprendenti vitamine idrosolubili a rilascio prolungato
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives

Also Published As

Publication number Publication date
NZ517833A (en) 2004-01-30
EP1210079A2 (en) 2002-06-05
WO2001013901A2 (en) 2001-03-01
RU2309733C2 (ru) 2007-11-10
AU6558900A (en) 2001-03-19
RU2002107015A (ru) 2003-11-10
WO2001013901A3 (en) 2001-09-07
PL356667A1 (en) 2004-06-28
JP2003507419A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
WO2001085212A3 (en) Drug delivery systems for photodynamic therapy
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
AU1046202A (en) Transdermal therapeutic system for treating restless-legs-syndrome
IL179012A0 (en) Method and composition for treating rhinitis
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
TW200510392A (en) Chemical compounds
AR025343A1 (es) Un sistema de suministro farmaceutico para vitamina c y vitamina e y uso de una combinacion de ambas para la preparacion de una droga para tratar oprevenir estados que involucran estres oxidante
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
TW200505452A (en) Chemical compounds
WO2003032946A3 (en) Ph-sensitive liposomes for targeted drug delivery
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
IT1284873B1 (it) Derivati stabili di ubichinolo procedimenti per la loro produzione e loro impiego farmaceutico
SE0102887D0 (sv) New formulation
AR026004A1 (es) Pirroles substituidos.